Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154872 | 0.87 | ALDH1A1 (0.52) | ALDH1A1ALOX15KMT2AATMPLK1 | |
| SCHEMBL29599305 | 0.87 | ALDH1A1 (0.52) | ALDH1A1ALOX15KMT2AATMPLK1 | |
| SCHEMBL13779511 | 0.86 | ALDH1A1 (0.38) | CYP1A2CNR2CNR1ALDH1A1ALOX15 | |
| SCHEMBL7717844 | 0.83 | CYP1A2 (0.59) | CYP1A2CNR2CNR1CYP2A6CYP3A4 | |
| SCHEMBL31347531 | 0.81 | CYP1A2 (0.56) | CYP1A2CNR2CNR1CYP2A6ALDH1A1 | |
| SCHEMBL7829452 | 0.81 | CYP1A2 (0.56) | CYP1A2CNR2CNR1CYP2A6ALDH1A1 | |
| SCHEMBL405225 | 0.81 | CYP1A2 (0.56) | CYP1A2CNR2CNR1CYP2A6ALDH1A1 | |
| SCHEMBL669648 | 0.81 | CYP1A2 (0.56) | CYP1A2CNR2CNR1CYP2A6ALDH1A1 | |
| SCHEMBL980390 | 0.81 | ALDH1A1 (0.47) | ALDH1A1ALOX15KMT2AATMMCL1 | |
| SCHEMBL10555469 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ALOX15KMT2AATMPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3807262-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | University of Washington (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | THE UNIV OF MONTANA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756061-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115987-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
| WO-1998037052-A1 | PREPARATION OF ARYL BROMOARYL KETONES AND CARBOXYLIC DERIVATIVES THEREOF | ALBEMARLE CORPORATION (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | CYP1A2 4551/4885CNR2 2189/4885CNR1 2023/4885 |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | CYP1A2 4551/4885CNR2 2189/4885CNR1 2023/4885 |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | CYP1A2 825/4885CNR2 1/4885CNR1 2/4885 |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | OPRM1, OPRL1, OPRD1 | CYP1A2 237/4885CNR2 16/4885CNR1 9/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CYP1A2 211/4885CNR2 11/4885CNR1 6/4885 |
| US-20170096426-A1 | Novel Tricyclic Modulators of Cannabinoid Receptors | CNR1, CNR2, OPRL1 | CYP1A2 1453/4885CNR2 2/4885CNR1 1/4885 |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | TUBB3, TUBB1, TUBA1C | CYP1A2 4551/4885CNR2 2189/4885CNR1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.